Skills this job asks for
LeadershipLean / Six SigmaComplianceGoogle Cloud
Add your CV (free) to see which of these your CV is missing.
Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordUSCIS Data Hub records 1 H-1B approvals for this employer in FY2023 — older 2023 data; no recent Department of Labor filings (Oct 2025 – Jun 2026) were found for it.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- USCIS Data Hub records 1 H-1B approvals for this employer in FY2023 — older 2023 data; no recent Department of Labor filings (Oct 2025 – Jun 2026) were found for it. Source: US Department of Labor visa filings (LCA) (US Department of Labor (OFLC), plus USCIS H-1B Employer Data Hub).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
At Aditum Bio, our mission is to rapidly translate scientific discoveries into new medicines. Cofounded by industry veterans Joe Jimenez, former CEO of Novartis and Mark Fishman, former President of the Novartis Institutes for Biomedical Research, the firm in-licenses promising therapies that for some reason are not advancing toward the clinic. The firm focuses on the translational phase of medicine to generate data that can support full clinical development, and eventual market launch, to reach patients in need.
Position Summary
The Senior Director, Clinical Operations will provide strategic and operational leadership for the planning and execution of assigned early-stage clinical development programs across Aditum Bio's portfolio of biotechnology companies. Reporting to the SVP, Clinical Development Operations, this individual will independently lead the clinical operations strategy and execution for assigned programs spanning clinical pharmacology studies (first-in-human, SAD/MAD, PK/PD, drug-drug interaction) and Phase I/II patient studies, partnering closely with portfolio company leadership and cross-functional teams to deliver high-quality clinical trials on time and within budget. The Senior Director will play a critical role in building scalable operational capabilities across the portfolio, overseeing CRO and vendor performance, mentoring clinical operations staff, and helping establish best practices across the portfolio. This role requires a collaborative leader who is equally comfortable serving as program lead and, where portfolio needs require it, as the study lead, developing operational strategy and rolling up their sleeves in a lean, fast-paced biotech incubator environment.
Position Responsibilities
Program Leadership
• Lead clinical operations for multiple early development programs (clinical pharmacology and Phase I/II) across Aditum Bio's portfolio companies.
• Develop operational strategy aligned with program and portfolio priorities, building and pressure-testing scenario plans across timeline, cost, enrollment, and risk to inform program- and portfolio-level decisions.
• Serve as a trusted partner to executive leadership and cross-functional teams.
Study Execution
• Lead studies from protocol development through closeout, driving global operational strategy, feasibility, enrollment planning, and risk mitigation.
• Ensure studies are delivered on time, within budget, and to the highest quality standards.
Cross-Functional & Vendor Leadership
• Lead cross-functional study teams and own the CRO and vendor lifecycle (e.g., selection, contract scope, oversight, and ongoing performance) that drive execution.
• Oversee study timelines, budgets, forecasts, resources, and vendor performance.
Quality & Continuous Improvement
• Ensure compliance with ICH-GCP and applicable global regulations while maintaining inspection readiness.
• Drive continuous improvement through scalable processes, SOPs, and operational best practices.
People & Innovation
• Develop and mentor clinical operations staff and external resources through direct or matrix leadership.
• Champion innovative approaches to trial execution, including digital technologies, decentralized trials, and AI-enabled operational analytics.
Qualifications
• Bachelor's degree in a scientific discipline; advanced degree preferred.
• At least 10 years of progressive clinical operations experience within biotechnology, pharmaceutical, or CRO organizations, including leadership responsibility for early-stage clinical programs.
• Demonstrated success leading the operational execution of both clinical pharmacology studies (first-in-human, SAD/MAD, PK/PD, drug-drug interaction, food effect) and Phase I/II patient studies, including global and multi-ce
Apply on employer site ↗